Page last updated: 2024-12-11

phencyclidine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9795678
CHEMBL ID542581
SCHEMBL ID21777
MeSH IDM0329830

Synonyms (41)

Synonym
v1jzq7gdtx ,
AKOS015844481
wln: t6ntj a- al6tj ar &gh
phenylcyclidine hydrochloride
phencyclidine hydrochloride
gp-121
sernylan
phencylidine hydrochloride
trank
956-90-1
cn-25,253-2
sernyl hydrochloride
nsc-40902
cl 395 hydrochloride
1-(1-phenylcyclohexyl)piperidine hydrochloride
nsc40902
c.i. 395
elysion
D05453
phencyclidine hydrochloride (usan)
piperidine, 1-(1-phenylcyclohexyl)-, hydrochloride
phencyclidine hydrochloride [usan]
phencyclidine hydrochloride cii
CHEMBL542581
phencyclidine hcl
cn-25253-2
phencyclidine monohydrochloride
FT-0602418
phencyclidine hydrochloride [mi]
phencyclidine hydrochloride cii [usp-rs]
phencyclidine hydrochloride [who-dd]
phencyclidine hydrochloride [mart.]
SCHEMBL21777
phencyclidine hydrochloride, united states pharmacopeia (usp) reference standard
DTXSID70893724
1-(1-phenylcyclohexyl)piperidine hcl
AMY24030
Q27291418
pcp (hydrochloride)
pcp.hcl (phencyclidine.hcl)
pcp.hcl (phencyclidine.hcl), 1mg/ml in methanol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
delta-type opioid receptorHomo sapiens (human)EC50 (µMol)17.29900.13203.58649.5690AID588407; AID588411
mu-type opioid receptor isoform MOR-1Homo sapiens (human)EC50 (µMol)3.62550.13203.30049.5690AID588407; AID588435
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID195690Ability to displace 7.0 nM [3H]PCP binding to rat brain homogenate relative to PCP (IC50= 270 nM)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Structure-activity relationships of the cycloalkyl ring of phencyclidine.
AID195553Inhibitory concentration for [3H]PCP binding to rat brain homogenate relative to PCP1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Structure-activity relationships of the cycloalkyl ring of phencyclidine.
AID74940Tested for its effect on Hypoxia induced neuronal damage1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents.
AID23796Half-life determined in the urine of monkey1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Mammalian metabolism of phencyclidine.
AID23795Half-life determined in the urine of dog1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Mammalian metabolism of phencyclidine.
AID57330Compound was evaluated for the mean locomotor activity (GABA-ergic agonism) by the difference in the counts between postinjection and preinjection activities.1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Mammalian metabolism of phencyclidine.
AID74941Tested for its effect on hippocampal neuronal damage in gerbils activity1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents.
AID187492Relative potency in the rat discriminative stimulus assay, expressed as mg of PCP (= 1.0 mg of compound)1981Journal of medicinal chemistry, Dec, Volume: 24, Issue:12
Structure-activity relationships of the cycloalkyl ring of phencyclidine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's1 (12.50)18.2507
2000's1 (12.50)29.6817
2010's3 (37.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.89

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.89 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.89)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]